NHS Framework Agreement for London, Branded Medicines - Tranche A and Annual
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Value | £276,524,326 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Deadline | 12 Apr 2022 |
| Procedure | open |
| OCID | ocds-h6vhtk-031f20 |
Awards (56)
This procurement was awarded to 30 suppliers. Values shown are per-award; the notice total is £276,524,326.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Abbvie Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Abbvie Ltd shared | · | · | active |
| Accord-UK Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Accord-UK Ltd shared | · | · | active |
| Almirall shared | £153,778,681 | 14 Jul 2022 | active |
| Almirall shared | · | · | active |
| Amgen Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Amgen Ltd shared | · | · | active |
| AstraZeneca shared | £153,778,681 | 14 Jul 2022 | active |
| AstraZeneca shared | · | · | active |
| Aventis Pharma ltd t/a Sanofi shared | £153,778,681 | 14 Jul 2022 | active |
| Aventis Pharma ltd t/a Sanofi shared | · | · | active |
| Celltrion Healthcare United Kingdom Limited shared | £153,778,681 | 14 Jul 2022 | active |
| Celltrion Healthcare United Kingdom Limited shared | · | · | active |
| Eli Lilly and Company Ltd shared | · | · | active |
| Eli Lilly & Company Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Gedeon Richter UK Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Gedeon Richter UK Ltd shared | · | · | active |
| GlaxoSmithKline UK Limited shared | £153,778,681 | 14 Jul 2022 | active |
| GlaxoSmithKline UK Limited shared | · | · | active |
| Ipsen shared | £153,778,681 | 14 Jul 2022 | active |
| Ipsen shared | · | · | active |
| Janssen-Cilag Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Janssen-Cilag Ltd shared | · | · | active |
| Merck Serono Limited shared | £153,778,681 | 14 Jul 2022 | active |
| Merck Serono Limited shared | · | · | active |
| Merck Sharpe and Dohme (UK) Limited shared | · | · | active |
| Merck Sharpe & Dohme (UK) Limited shared | £153,778,681 | 14 Jul 2022 | active |
| Merz shared | £153,778,681 | 14 Jul 2022 | active |
| Merz shared | · | · | active |
| Novo Nordisk shared | £153,778,681 | 14 Jul 2022 | active |
| Novo Nordisk shared | · | · | active |
| Organon Pharmaceuticals UK Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Organon Pharmaceuticals UK Ltd shared | · | · | active |
| Pfizer Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Pfizer Ltd shared | · | · | active |
| Pharmacosmos UK Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Pharmacosmos UK Ltd shared | · | · | active |
| Roche Products Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Roche Products Ltd shared | · | · | active |
| Sandoz Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Sandoz Ltd shared | · | · | active |
| Sobi (Swedish Orphan Biovitrum Ltd) shared | £153,778,681 | 14 Jul 2022 | active |
| Sobi (Swedish Orphan Biovitrum Ltd) shared | · | · | active |
| Takeda UK Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Takeda UK Ltd shared | · | · | active |
| Teva UK Limited shared | £153,778,681 | 14 Jul 2022 | active |
| Teva UK Limited shared | · | · | active |
| Thornton and Ross Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Thornton and Ross Ltd shared | · | · | active |
| UCB Pharma Ltd (primary) shared | £153,778,681 | 14 Jul 2022 | active |
| UCB Pharma Ltd (primary) shared | · | · | active |
| Vifor Pharma UK Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Vifor Pharma UK Ltd shared | · | · | active |
| Zentiva Pharma UK Ltd shared | £153,778,681 | 14 Jul 2022 | active |
| Zentiva Pharma UK Ltd shared | · | · | active |
description
NHS London Branded Medicines - Tranche A <br/><br/>Offer reference number: CM/PHR/20/5614<br/><br/>CM/PHR/20/5614/01 - NHS Framework for LONDON Branded Medicines - Tranche A. Period of framework: 1 September 2022 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months<br/><br/>CM/PHR/20/5614/02 - NHS Framework for the LONDON Branded Medicines - Annual Tranche. Period of framework: 1 September 2022 to 31 August 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.
notice history
3 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 8 Mar 2022 | Contract notice (F02) | Earlier regulations | 006279-2022 |
| 11 Aug 2022 | Contract award notice (F03) | Earlier regulations | 022184-2022 |
| 11 Aug 2022 | Award (award) | · | 974d783d-e4b1-4113-94d0-4a6a623ae6f3-563051 |
more from NHS England
- Urgent Award - haematological screening · £16,202 · 29 Jul 2026
- HSCN-AWS Connectivity Service for Spine · £228,060 · 29 Jul 2026
- Incentive Voucher Provider · £60,000 · 29 Jul 2026
- CRM for NHSE participant/candidate data 26-27 · £56,640 · 28 Jul 2026
- Wayfinder and First Contact Digital Clinical Support 2026-27 · £748,000 · 23 Jul 2026
- Support Services for PPM application · £860,000 · 22 Jul 2026
- Digital Maturity Assessment · 21 Jul 2026
- Integrated Healthcare Services to Haslar Immigration Removal Centre (IRC) · £19,052,186 · 13 Jul 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.